| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Galectin Therapeutics Inc. (GALT) have been net sellers, shedding 98,287 shares worth roughly $496K on balance. In the past 30 days, 0 insiders bought and 1 sold. Sales set the recent tone.
On the other side, 1 insider reduced a position over the period. GALT sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 5.61M | $19.37M | - | |
| CFO | 100.0K | $345.0K | - | |
| CEO | 100.0K | $345.0K | - | |
| Dir | 60.0K | $207.0K | - | |
| Dir | 60.0K | $207.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2015 | Freeman Kevin D57 | Director | Buy | 2,083 | $2.70 | $5,624.10 | New | |
| Jun 1, 2015 | Traber Peter G59 | President &CEO | Buy | 4,000 | $2.53 | $10,120.00 | +3.9% |